J&J inks a $1.15B discovery deal with PeptiDream; Medivir plots PhIII HDAC program

→ Tokyo-based PeptiDream has struck a discovery deal with J&J worth up to $1.15 billion. In the deal PeptiDream will use its platform tech to “identify macrocyclic/constrained peptides against multiple metabolic and cardiovascular targets of interest selected by Janssen, and to optimize hit peptides into therapeutic peptides or small molecule products.”

→ Sweden’s Medivir says that they’ve gathered some positive results from a Phase II study of their HDAC inhibitor remetinostat for cutaneous T-cell lymphoma. Early stage patients in the 1% remetinostat gel BID arm had the highest proportion of confirmed responses (8/20, 40%), including one complete response. The biotech says it is now planning a pivotal Phase III program.

→ Galenica Sante has now completed its IPO, separating from Vifor Pharma Group, which will now focus entirely on the pharmaceuticals side of the business as Galenica hives off health and beauty.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->